Join
Live feed
·
PRReleasevia Quantisnow
Xencor Inc. logo

Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

ByQuantisnow·Wall Street's wire, on your screen.
XNCR· Xencor Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XNCR (Xencor Inc.) and more on Quantisnow.